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Abstract
Background: In the care of hypertension, it is important that health professionals possess available tools that allow 
evaluating the impairment of the health-related quality of life, according to the severity of hypertension and the risk for 
cardiovascular events. Among the instruments developed for the assessment of health-related quality of life, there is the 
Mini-Cuestionario of Calidad de Vida en la Hipertensión Arterial (MINICHAL) recently adapted to the Brazilian culture.
Objective: To estimate the validity of known groups of the Brazilian version of the MINICHAL regarding the classification 
of risk for cardiovascular events, symptoms, severity of dyspnea and target-organ damage.
Methods: Data of 200 hypertensive outpatients concerning sociodemographic and clinical information and health-related 
quality of life were gathered by consulting the medical charts and the application of the Brazilian version of MINICHAL. 
The Mann-Whitney test was used to compare health-related quality of life in relation to symptoms and target-organ 
damage. The Kruskal-Wallis test and ANOVA with ranks transformation were used to compare health-related quality of 
life in relation to the classification of risk for cardiovascular events and intensity of dyspnea, respectively.
Results: The MINICHAL was able to discriminate health-related quality of life in relation to symptoms and kidney damage, 
but did not discriminate health-related quality of life in relation to the classification of risk for cardiovascular events.
Conclusion: The Brazilian version of the MINICHAL is a questionnaire capable of discriminating differences on the 
health-related quality of life regarding dyspnea, chest pain, palpitation, lipothymy, cephalea and renal damage. (Arq Bras 
Cardiol. 2015; 104(4):299-307)
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Introduction
Arterial hypertension (AH) is a highly prevalent disease 
worldwide. It is a major condition for an increased risk 
of cardiovascular morbidity and mortality1-3. Studies4,5 
have demonstrated that hypertensive patients with target 
organ damage (TOD) have a worse prognosis than patients 
with non-complicated AH, because of the high risk for 
cardiovascular events among those with vascular damage6,7. 
Although common, high-risk AH is underdiagnosed or 
undertreated, and this has prompted the foreign guidelines 
to recommend that its management be based on the 
assessment of blood pressure levels and of the overall 
cardiovascular risk6-9.
Early detection of hypertensive damage enables the 
introduction of drug therapy, thus contributing for the 
reduction of AH-related cardiovascular events and for 
a better prognosis10, as well as for the improvement of 
health-related quality of life (HRQoL).
An adequate measurement of HRQoL is a challenge for 
health professionals, researchers and health policy makers11, 
and this has encouraged the construction and validation 
of HRQoL measurement instruments. Among the types of 
validity, that of known groups, which tests the difference 
of characteristics measured among two or more groups 
of subjects12, is of great interest in the clinical practice 
because it permits the verification of the instrument’s ability 
to discriminate groups with distinct characteristics such as 
different levels of severity of disease.
In the care of hypertensive patients, it is important for 
health professionals to have tools to enable them to assess 
the impact on HRQoL13 according to the severity of AH and 
the risk for cardiovascular events; this should contribute for 
the design of specific interventions14.
Among the instruments created to assess HRQoL, we 
point out the Mini-Cuestionario de Calidade de Vida em la 
Hipertensión Arterial (MINICHAL)15-18, recently adapted for 
Brazil19. The Brazilian version showed evidences of reliability 
and validity19-21, and proved to be able to discriminate 
normotensive from hypertensive individuals19. 
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Since the severity of AH can be assessed according to 
different clinical criteria, the objective of this study was to 
estimate the validity of known groups of the Brazilian version of 
MINICHAL among hypertensive individuals, in relation to the 
classification or risk for cardiovascular events, the occurrence 
of TOD, the presence of symptoms and severity of dyspnea.
Methods
Research centers
This research was carried out in an AH outpatient service of 
a university hospital and in a Basic Health Unit (UBS – Unidade 
Básica de Saúde), both located in the State of Sao Paulo.
Subjects
A total of 200 hypertensive patients with ages 18 years 
and above, and being followed up on an outpatient basis for 
at least 6 months were enrolled in this study. Patients with 
secondary AH, comorbidities of great impact on HRQoL 
(such as neoplasia and dialytic kidney failure), chronic lung 
diseases not related to AH (to exclude patients with dyspnea 
not related to AH), and those unable to comprehend and 
communicate verbally.
Sampling process
The sample size was calculated based on the difference 
between the means of MINICHAL domains observed in a pilot 
study (n = 27). Considering alpha of 0.05 and a test power 
of 80% (beta of 0.20), a total of 200 subjects was estimated. 
In order to achieve the minimum estimated sample size, 
patients who met the inclusion criteria and did not meet any 
of the exclusion criteria were enrolled sequentially until the 
established n was reached.
Data collection
Data were collected by the principal investigator in the 
research centers previously mentioned, from May to December 
2009, after the participants had given written informed consent 
(WIC). The method of available data recording was used 
to obtain sociodemographic data from the medical records 
(gender, skin color, age and marital status). To determine the 
overall cardiovascular risk according to international guidelines7, 
the following clinical variables were obtained: family history of 
early cardiovascular disease (in women with less than 65 years of 
age and men with less than 55); history of previous and current 
cigarette smoking; dyslipidemias; diabetes mellitus (DM) and/
or glucose intolerance (plasma glucose levels between 102 
and 125 mg/dL); hyperuricemia (uric acid > 7 mg/dL for men 
and > 6.5 mg/dL for women); obesity (body mass index – BMI 
> 30 kg/m2); and abdominal obesity (waist circunference – WC 
> 102 cm for men and > 88 cm for women7).
Definition of target organ damage
In the present study, TOD was considered as kidney 
function abnormalities (microalbuminuria, decreased 
creatinine clearance and increased serum creatinine), cardiac 
abnormalities (echocardiographic evidence of left ventricular 
hypertrophy – LVH, and diastolic dysfunction), vascular 
diseases, and hypertensive retinopathy. LVH was defined 
by the ratio left ventricular mass / body surface ≥ 125 g/m2 
for men and ≥ 110 g/m2 for women22. Diagnosis of diastolic 
dysfunction was retrieved from Doppler echocardiography 
reports. The presence of at least one atherosclerotic plaque 
(defined as focal thickening > 1.3 mm in any segment of the 
carotid arteries23 and/or presence of diffuse wall thickening, 
with mean common carotid artery thickness > 0.9 mm) 
was considered evidence of vascular abnormalities7. 
Hypertensive retinopathy was diagnosed by the presence 
of the following abnormalities on fundoscopy, as performed 
by an ophthalmologist: arteriolar narrowing and light reflex 
changes (grade 1); arteriolar narrowing, more marked 
reflex changes and arteriovenous nicking (grade 2); grade 2 
abnormalities, retinal hemorrhage and exudates (grade 3); or 
grade 3 abnormalities and papilledema (grade 4), according 
to the Keith-Wagener-Barker classification24.
After data collection from the medical records, the 
patients were submitted to interview for collection of 
sociodemographic data (years of schooling, employment 
status, and monthly personal and family income) and clinical 
data, such as the presence of symptoms (dyspnea, chest pain, 
fatigue, headache, palpitations, and presyncope), measured 
as dichotomous variables (yes/no). The purpose of interview 
was also to obtain information regarding HRQoL by means 
of the administration of the Brazilian version of MINICHAL. 
For hypertensive patients reporting dyspnea, severity of 
symptom was assessed by means of the Brazilian version of 
the instrument Medical Research Council (MRC)25.
Instruments
MINICHAL consists of the short version18 of Calidad de 
Vida em la Hipertensión Arterial (CHAL), developed and 
validated in Spain14-16. This is a self-administered instrument 
comprised of 16 items divided into the Mental Status (1 to 
10) and Somatic Manifestations (11 to 16) dimensions, in 
addition to one general question on quality of life, which 
is not included in any of the dimensions. The items address 
the past 7 days, by means of a Likert scale with the following 
four possible answers: zero (absolutely not); 1 (yes, a little); 
2 (yes, enough); and 3 (yes, a lot). The total score is obtained 
by the sum of the items, and ranges from zero to 30 for the 
Mental Status dimension, and from zero to 18 for the Somatic 
Manifestations dimension; the closer to zero, the better the 
quality of health. The question on general perception of health 
is scored with the same possible answers, but is not considered 
in the total score sum.
In the present study, the Brazilian version of MINICHAL 
was used. However, for the total score sum, the composition 
of dimensions of the original instrument18 was considered, 
since in the validation study for the Brazilian context19, item 10 
was excluded from the Mental Status dimension and included 
in the Somatic Manifestations dimension, and the question 
regarding the overall perception of health was included as the 
17th question. The total score was calculated when the number 
of missing questions did not exceed 25% of the total items 
administered, i.e., when the number of valid items was equal 
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Table 1 – Sociodemographic characteristics of the hypertensive individuals (n = 200) being followed up on an outpatient basis in a university 
hospital and Basic Health Unit, Campinas, 2009, 2010
Sociodemographic variables n % Mean (SD) Median Variation
Age (years) 200 57 (11.3) 57 21-82
Female gender 116 58.0
Caucasian 129 64.5
Level of education (years) 6 (4.1) 4 0-16
Marital status with partner 123 61.5
Employment status (n = 198)
Inactive 81 40.5
Active 76 38.0
Housewife 42 21.0
Income, MW*
Monthly Personal income 199 1.6 (1.5) 1.29 0.0-8.6
Monthly family income 197 3.2 (2.1) 2.58 0.0-12.9
* MW in the period of data collection was R$465.00 (US$265.71). MW: minimum wage; SD: standard deviation.
to 8 and 5 in the Mental Status and Somatic Manifestations 
dimensions, respectively21. The question on general perception 
of health was not considered in the total score sum, like in 
the validation study18. Although the instrument had been 
originally developed to be self-administered, given the low level 
of education of participants, it was decided that it would be 
administered by means of an interview. MINICHAL reliability 
was evaluated as for its internal consistency by means of the 
calculation of Cronbach’s alpha (α) coefficient. α values of 0.85, 
0.84 and 0.59 were verified for the total score sum, Mental Status 
dimension, and Somatic Manifestations dimension, respectively.
MRC is an instrument developed and validated in England 
to measure the severity of dyspnea in patients with obstructive 
pulmonary diseases26, and comprises five items, with 
answer scores ranging from 1 to 5. Grade 1 corresponds to 
breathlessness on strenuous exercise; grade 2, to breathlessness 
hurrying on the level or up a slight hill; grade 3, when walking 
slower than people of the same age because of breathlessness or 
having to stop for breath even when walking at their own pace; 
grade 4, when having to stop after walking less than 100 m or 
after a few minutes; and grade 5, when breathlessness prevents 
from leaving the house or when dressing. The version adapted 
for the Brazilian context was used25.
Data analysis
Data were entered into the Excel for Windows 2003 
software and transported to the Statistical Analysis System (SAS) 
for Windows version 9.02 software for descriptive analyses (of 
frequency for categorical variables; mean, median, standard 
deviation and variation for continuous variables) and comparison 
(between means of psycosocial variables). Since the variable of 
interest was non-normally distributed, non-parametric tests were 
used. The Mann-Whitney test was used to compare the HRQoL 
scores in relation to symptoms, and the Analysis of Variance 
(ANOVA) with rank transformation, to compare HRQoL among 
hypertensive patients with different levels of dyspnea25, followed 
by the Tukey’s test to locate differences. The Kruskal-Wallis test 
was used to compare HRQoL scores among hypertensive patients 
stratified according to their risk for cardiovascular events7, as 
follows: low, if stage-1 AH, with no risk factor (RF); moderate, 
if stage-1 AH, with one to two RF and stage-2 AH, with no RF 
or with one to two RF; high, if stages 1 or 2 AH, with three or 
more RF or TOD or DM; and very high, if stages 1 or 2 AH and 
cardiovascular disease and stage-3 AH, with one to two RF and/or 
with three or more RF or TOD or DM or cardiovascular disease. 
Findings were considered significant when p value < 0.05.
Ethical aspects
The study was approved by the local Research Ethics 
Committees (report 1083/2008), according to the Declaration 
of Helsinki.
Results
The sample (n = 200) was mostly comprised of women 
(58%);with a mean age of 57 (11.3) years; Caucasians (64.5%); 
living with a partner (61.5%); economically active (59.0%); 
with a mean schooltime of 6.0 (4.1) years; and mean personal 
and family income of 1.6 (1.5) and 3.2 (2.1) minimum wages 
per month, respectively (Table 1).
The group was characterized by a mean time of 12.6 
(10.5) years of AH, with a mean of 3.1 (1.7) associated 
clinical conditions and/or RF. Half the group showed more 
than two associated symptoms; 42.5% had TOD, especially 
LVH and mean use of 3.6 (2.4) medications/day. Half the 
sample showed high and/or very high risk for the occurrence 
of cardiovascular events (50.5%); 16.5% of the subjects 
were considered with no risk for cardiovascular events, 
since their blood pressure levels fit the optimal/normal/
borderline stage (Table 2).
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Table 2 – Clinical characteristics of the hypertensive patients (n = 200) being followed up on an outpatient basis in a university hospital and 
Basic Health Unit, Campinas, 2009, 2010
Clinical variables n % Mean (SD) Median Variation
Time of arterial hypertension (years) 198 12.6 (10.5) 10 1-53
Associated risk factors/clinical conditions
Dyslipidemia 133 66.5
Abdominal obesity (WC*) 132 66.0
Family history of cardiovascular disease 117 58.5
Obesity (BMI†) 90 45.0
Metabolic syndrome 82 41.0
Glucose intolerance¶ 55 27.5
Diabetes mellitus 32 16.2
Hyperuricemia§ 31 15.5
Current cigarette smoking 21 10.5
Number of associated clinical conditions 3.1 (1.7) 3 0-7
Acute coronary syndrome and/or myocardial revascularization 26 13.0
Heart failure 12 6.0
Stroke/transient ischemia 10 5.0
Peripheral artery disease 6 3.0
Target organ damage
LVH‡ 85 42.5
Diastolic dysfunction 80 40.0
Hypertensive renal damage†† 21 10.5
Hypertensive retinopathy¶¶ 21 10.5
Carotid thickening§§ 6 3.0
Symptoms
Headache 94 47.0
Palpitations 71 35.5
Lipotimia 57 28.5
Dyspnea 57 28.5
Chest pain 54 27.0
Number of associated symptoms 2.1 (1.6) 2 0-6
Number of medications used 3.6 (2.4) 3 0-11
Risk stratification for cardiovascular events‡‡
No risk 33 16.5
Low risk 29 14.5
Moderate risk 37 18.5
High risk 65 32.5
Very high risk 36 18.0
* WC > 102 cm for men and > 88 cm for women; † BMI > 30 kg/m2; ¶ blood glucose between 102-125 mg/dL; § uric acid > 7 mg/dL for men and > 6.5 mg/dL for women; 
‡ LVH ≥ 125 g/m2 ffor men and ≥ 110 g/m2 for women; †† hypertensive renal damage: creatinine clearance ≤ 60 mL/minute and/or serum creatinine > 1.5 mg/dL for men 
and > 1.4 mg/dL for women and/or microalbuminuria > 300 mg/24 hours; ¶¶ hypertensive retinopathy: arteriolar narrowing and light reflex changes (grade 1); arteriolar 
narrowing and more marked reflex changes and arteriovenous nicking (grade 2); grade 2 changes, retinal hemorrhages and exudates (grade 3); or grade 3 changes 
and papilledema (grade 4) on fundoscopy; §§ intima-media > 0.9 mm; ‡‡ according to the European Society of Hypertension/European Society of Cardiology Guidelines7. 
SD: standard deviation; WC: waist circumference; BMI: body mass index; LVH: left ventricular hypertrophy. 
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Construct validity: assessment of known groups
The construct validity of the Brazilian version of MINICHAL 
was verified by means of the assessment of known groups.
 It has been hypothesized that hypertensive patients with 
symptoms (dyspnea, chest pain, presyncope, palpitations 
and headache), TOD and high risk for cardiovascular 
events would have a significantly higher HRQoL score than 
hypertensive patients with no complications, i.e., with no 
symptoms, no TOD, and at a low risk for cardiovascular 
events, according to international guidelines.
Significantly higher HRQoL scores were observed among 
those with renal damage in comparison to hypertensive 
patients with preserved renal function, as regards the 
Somatic Manifestations dimension and total MINICHAL 
score. However, no significant difference was observed in 
the comparison of HRQoL scores between patients with or 
without LVH, as well as between those with and without 
diastolic dysfunction and/or hypertensive retinopathy (Table 3).
We verified that hypertensive patients reporting symptoms 
showed significantly higher scores (worse HRQoL) in both 
dimensions and total score of the Brazilian version of 
MINICHAL when compared to those without symptoms.
In addition, the Brazilian version of MINICHAL was proven 
to be able to discriminate HRQoL among hypertensive patients 
without and with different levels of dyspnea (Table 4).
However, no dimension of the Brazilian version of 
MINICHAL was able to discriminate HRQoL between patients 
classified as without and/or at a low/moderate risk and those 
at a high/very high risk for cardiovascular events (Table 5).
Discussion
The objective of this study was to broaden the assessment 
of the validity of known groups of the Brazilian version of 
MINICHAL. Thus, the ability of this instrument to discriminate 
hypertensive patients in relation to the severity of AH was 
investigated, according to criteria for the classification of risk for 
cardiovascular events and the occurrence of TOD, as well as in 
relation to the presence of symptoms and severity of dyspnea.
Our findings showed that the Brazilian version of 
MINICHAL was not able to discriminate hypertensive 
patients according to the criteria used for the classification 
of severity of AH. No significant difference was observed 
in HRQoL measurement in the different stages of risk for 
cardiovascular events, or among patients with and without 
TOD, except for renal dysfunction.
However, the instrument was sensitive to show differences 
in HRQoL according to the presence of all the symptoms 
analyzed. In this regard, our findings are important and point 
to a significant perspective to be considered in the follow-up 
of hypertensive patients. Classically, AH is described as an 
asymptomatic condition. Nonetheless, in clinical practice, 
AH is associated with the presence of cardiovascular 
symptoms, probably because of the presence of other 
comorbidities14. In the present study, 50% of patients had 
more than two associated symptoms, and this corroborates 
the importance of the assessment of cardiovascular symptoms 
throughout the clinical follow-up of hypertensive patients.
In the validation study of the original version of MINICHAL 
in the Spanish population18, significant differences were 
observed in the Somatic Manifestations score among 
hypertensive patients classified according to the stages of 
severity of AH proposed by the World Health Organization 
(stage I, with no signs of TOD; stage II, with one sign or 
symptom of TOD; or stage III, ≥ 1 sign and symptom of 
TOD)27. However, it is important to emphasize that the HRQoL 
measurement was different only regarding the comparison 
between stage-I patients (no signs of TOD and probably with 
no symptoms) and those of clustered stages II and III, in which 
the presence of symptoms was expected. 
In a previous study assessing HRQoL of hypertensive 
patients using a generic instrument, correlation between 
echocardiographic changes resulting from AH and HRQoL 
was verified only for the group presenting with dyspnea. 
For the group without this symptom, there was no 
correlation between variables. Thus, the findings point to 
dyspnea as an important moderator in the relation between 
HRQoL and one of the indicators of severity of disease, 
because of the echocardiographic abnormalities14. 
Another Brazilian study28 used the Medical Outcomes 
Study 36 – Item Short – Form Health Survey (SF-36) to 
evaluate HRQoL of 100 hypertensive patients participating in 
an interdisciplinary experimental study based on educational 
activities. No changes in the quality of life were detected among 
the intervention and control groups, and this was attributed to 
the characteristic of systemic AH of being asymptomatic.
It is possible that the relatively small case series of the 
present study has contributed to the absence of significant 
findings as regards the ability of the Brazilian version of 
MINICHAL to discriminate different stages of severity of 
AH. However, the low variability of scores in the different 
stages weakens this hypothesis. It is hypothesized that the 
severity of AH, when assessed according to the presence 
or absence of cardiovascular symptoms, is an indicator 
of changes in HRQoL. This assumption corroborates the 
importance of the assessment of symptoms throughout 
the follow-up of hypertensive patients so that the 
pharmacological and non-pharmacological approaches be 
adjusted also as a function of HRQoL, which is affected 
by the manifestation of symptoms.
In the present study, the fact that the Brazilian version 
of MINICHAL was not able to discriminate HRQoL 
between hypertensive patients with and without LVH may 
be explained by the inclusion of hypertensive patients 
with structural cardiac changes, whether symptomatic or 
asymptomatic. In the Spanish study18, the hypertensive 
patients were grouped according to the presence of signs 
and symptoms of TOD, which may have contributed to 
the discrimination of HRQoL, since MINICHAL seems 
to be sensitive in the detection of differences in HRQoL 
in the presence of symptoms. The Brazilian version of 
MINICHAL was also not able to discriminate HRQoL among 
patients allocated at the extremes of the classification of 
risk for cardiovascular events, which considers AH stages, 
coexistence of RF, cardiovascular disease, and TOD. 
The small number of patients distributed in the different strata 
of the classification may have contributed to this finding.
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Table 3 – Scores of the Brazilian version of MINICHAL, according to clinical variables of hypertensive patients followed up on an outpatient 
basis (n = 200), Campinas, 2009, 2010
Domains of the Brazilian version of MINICHAL
Mental Status Somatic Manifestations Total score 
n Mean (SD) Mean (SD) Mean (SD)
LVH†
Yes 85 6.3 (5.3) 3.3 (2.6) 9.6 (6.8)
No 115 7.0 (5.5) 3.5 (2.7) 10.5 (7.2)
P value* NS NS NS
Hypertensive retinopathy ¶
Yes 21 6.2 (4.3) 3.9 (3.1) 10.1 (6.9)
No 179 6.8 (5.6) 3.4 (2.6) 10.1 (7.0)
P value* NS NS NS
Renal damage§
Yes 21 7.7 (4.5) 4.8 (3.2) 12.5 (5.9)
No 179 6.6 (5.5) 3.3 (2.5) 9.9 (7.1)
P value* NS < 0.05 < 0.05
Diastolic function‡
Yes 80 6.7 (5.9) 3.4 (2.7) 10.1 (7.5)
No 83 6.9 (4.7) 3.7 (2.6) 10.7 (6.2)
P value* NS NS NS
Dyspnea
Yes 57 8.9(6.9) 4.9 (2.9) 13.9 (8.6)
No 143 5.8 (4.5) 2.8 (2.3) 8.7 (5.7)
P value* < 0.01 < 0.001 < 0.001
Chest pain
Yes 54 9.2 (6.7) 5.3 (3.0 ) 14.5 (7.9)
No 146  5.8 (4.6) 2.7 (2.1) 8.5(5.9)
P value* < 0.001 < 0.001 < 0.001
Presyncope
Yes 57 8.0 (5.9) 4.0 (2.5) 12 (7.3)
No 143 6.2 (5.2) 3.2 (2.7) 9.4 (6.8)
P value* < 0.05 < 0.05 < 0.05
Palpitations
Yes 71 9.0 (6.6) 4.9 (3.0) 13.9 (8.1)
No 129 5.4 (4.2) 2.6 (2.0) 8.1 (5.4)
P value* < 0.001 < 0.001 < 0.001
Headache
Yes 94 8.2 (5.7) 4.0 (2.7) 12.2 (7.2)
No 106 5.4 (4.9) 2.9 (2.5) 8.3 (6.4)
P value* < 0.001 < 0.01 < 0.001
* Mann-Whitney test; † left ventricular hypertrophy: ventricular mass/body surface ≥ 125 g/m2 for men and ≥ 110 g/m2 for women; ¶ hypertensive retinopathy: presence 
of arteriolar narrowing and venous dilatation (type 1); arteries with spasms and pathological arteriovenous nicking (type 2); obvious arterial narrowing and irregularities, 
flame-shaped hemorrhage or cotton-wool spots (type 3); or papilledema associated with types 1, 2 and 3 (type 4) on fundoscopy; § renal damage: creatinine clearance 
≤ 60mL/minute or serum creatinine > 1.5 mg/dL for men and > 1.4 mg/dL for women or microalbuminúria > 300 mg/24 hours; ‡ diastolic dysfunction: retrieved from 
Doppler echocardiogram report. SD: standard deviation; NS: not significant; LVH: left ventricular hypertrophy.
Conclusion
The findings of this study permit the conclusion that the 
Brazilian version of MINICHAL is an instrument able to 
discriminate differences in the health-related quality of life in 
relation to the symptoms of dyspnea, chest pain, palpitations, 
presyncope and headache, as well as to the presence 
of renal damage (target organ damage). However, the 
Brazilian version of MINICHAL was not able to discriminate 
health-related quality of life among hypertensive patients 
allocated at the extremes of the classification of risk for 
cardiovascular events. Further studies with larger sample sizes 
are recommended to elucidate the ability of the Brazilian 
version of MINICHAL to discriminate health-related quality 
of life in hypertensive patients with different degrees of 
severity of the disease.
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Table 4 – Scores of the Brazilian version of MINICHAL, according to the severity of dyspnea in outpatient hypertensive patients (n = 200), 
Campinas, 2009, 2010
Domains of the Brazilian version of MINICHAL
Mental Status Somatic manifestations Total score 
n Mean (SD) p value* Mean (SD) p value Mean (SD) p value
Grade 0 – no dyspnea 145 5.8 (4.6) < 0.01† 2.8 (2.3) < 0.001¶ 8.7 (5.8) < 0.001§
Grade 1 – breathlessness on strenuous exercise 9 8.3 (10.0) 2.9 (2.5) 11.2 (12.3)
Grade 2 – breathlessness hurrying on the level 
or up a light hill 18 7.9 (5.7) 4.5 (2.8) 12.4 (7.0)
Grade 3 – Walks slower than people of the same 
age because of breathlessness or has to stop for 
breath even when walking at his/her own pace 
6 10.0 (5.3) 6.7 (3.0) 16.7 (7.4)
Grade 4 – Has to stop for breath after walkin less 
than 100 m or after a few minutes 12 9.9 (7.3) 5.7 (3.0) 15.6 (9.4)
Grade 5 – Breathlessness prevents from leaving 
the house or when dressing 10 10.3 (5.7) 6.0 (2.7) 16.3 (15.2)
* ANOVA with rank transformation, followed by Tukey test: † degree 0 ≠ degree 5; ¶ degrees 3, 4, 5 ≠ 0; § degrees 4, 5 ≠ 0.
Table 5 – Scores of the Brazilian version of MINICHAL, according to the risk for cardiovascular events of hypertensive patients followed up on 
an outpatient basis (n = 200), Campinas, 2009, 2010
Domains of the Brazilian version of MINICHAL
Mental Status Somatic manifestations Total score 
n Mean (SD) p value* Mean (SD) p value Mean (SD) p value
Cardiovascular risk stratification†
No additional risk 33 7.3 (6.8) NS 3.4 (2.5) NS 10.7 (8.5) NS
Low risk 29 6.1 (5.0) 2.9 (2.5) 9.0 (6.6)
Moderate risk 37 7.1 (6.0) 3.3 (2.1) 10.4 (7.5)
High risk 65 6.8 (5.1) 3.6 (2.8) 10.3 (6.6)
Very high risk 36 6.1 (4.5) 3.9 (3.0) 10.0 (6.4)
Cardiovascular risk stratification¶
No/ low and/ or moderate risk 99 6.9 (6.0) NS 3.2 (2.4) NS 10.1 (7.6) NS
High/ very high risk 101 6.5 (4.9) 3.7 (2.9) 10.2 (6.5)
* Kruskal-Wallis test; † European Society of Hypertension/European Society of Cardiology Guidelines7; ¶ Clustered cardiovascular risk stratification. SD: standard 
deviation; NS: not significant.
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